Featured Research

from universities, journals, and other organizations

COX-2 Enzyme Instrumental In Parkinson's Disease

Date:
April 8, 2003
Source:
Columbia University College Of Physicians And Surgeons
Summary:
Research by neurologists at Columbia University suggests that COX-2 inhibitors like Celebrex and Vioxx may someday help Parkinson's disease patients by preventing the death of neurons that characterizes the disease.

New York, NY, April 7, 2003 – Research by neurologists at Columbia University suggests that COX-2 inhibitors like Celebrex and Vioxx may someday help Parkinson's disease patients by preventing the death of neurons that characterizes the disease.

COX-2 enzymes are more familiar in arthritis, but the enzymes produce inflammation in all damaged tissues, including the brain. Many researchers now see the inflammation as a critical process in neurodegenerative diseases, and studies have shown that non-steroidal anti-inflammatory drugs (NSAIDS) reduce the risk of developing Alzheimer's disease.

To see if COX-2 plays a role in Parkinson's disease, Dr. Serge Przedborski, professor of neurology and pathology in the College of Physicians & Surgeons and faculty member in the Columbia University Center for Neurobiology and Behavior, and postdoctoral researcher Dr. Peter Teismann looked for the enzyme in postmortem brains of Parkinson's patients. They found higher levels of COX-2 in the dopamine neurons of patients than in the neurons of brains without the disease. Dopamine neurons suffer the most damage from the disease.

The researchers then tested the importance of COX-2 in mice that have a disease similar to Parkinson's. The mice have the same high level of COX-2 in their dopamine neurons as patients do, making the mouse a valuable model for studying the human disease.

COX-2 was found to have an instrumental role in the death of the neurons. When the COX-2 enzyme was removed from the mice, or inhibited with a COX-2 inhibitor, more dopamine neurons were able to survive. Rofecoxib, the COX-2 inhibitor, doubled the number of surviving neurons: 88 percent survived with the drug, while only 41 percent survived without the drug.

Surprisingly, however, the COX-2 enzyme does not kill neurons through inflammation. When the enzyme was removed from mice or inhibited with a drug, the researchers did not see the reduction in inflammation they expected to see.

Instead, they found that the COX-2 enzyme may kill by oxidizing other molecules in the dopamine neurons. The oxidized molecules then react with and damage other components of the cell. Excessive damage can kill the cell.

Many researchers have hypothesized that oxidative damage kills neurons in Parkinson's disease.

"Regardless of how COX-2 works in Parkinson's disease, the benefit we see in animal models with COX-2 inhibitors suggests the drugs could be useful in slowing the disease's progression in patients," Dr. Przedborski says. "The drugs are safe and they get into the brain reasonably well."

The National Institute on Aging sponsors a multi-center trial testing COX-2 inhibitors in Alzheimer's patients. Dr. Przedborski says researchers are planning new trials to test the drug in Parkinson's patients.

This study was funded, in part, by grants from the National institutes of Health/National Institute of Neurological Disorders and Stroke, the U.S. Department of Defense, and the Parkinson's Disease Foundation, New York.


Story Source:

The above story is based on materials provided by Columbia University College Of Physicians And Surgeons. Note: Materials may be edited for content and length.


Cite This Page:

Columbia University College Of Physicians And Surgeons. "COX-2 Enzyme Instrumental In Parkinson's Disease." ScienceDaily. ScienceDaily, 8 April 2003. <www.sciencedaily.com/releases/2003/04/030408085115.htm>.
Columbia University College Of Physicians And Surgeons. (2003, April 8). COX-2 Enzyme Instrumental In Parkinson's Disease. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2003/04/030408085115.htm
Columbia University College Of Physicians And Surgeons. "COX-2 Enzyme Instrumental In Parkinson's Disease." ScienceDaily. www.sciencedaily.com/releases/2003/04/030408085115.htm (accessed October 23, 2014).

Share This



More Health & Medicine News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
More People Diagnosed With TB In 2013, But There's Good News

More People Diagnosed With TB In 2013, But There's Good News

Newsy (Oct. 22, 2014) The World Health Organizations says TB numbers rose in 2013, but it's partly due to better detection and more survivors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins